Identification of diphtheria toxin via screening as a potent cell cycle and p53-Independent cytotoxin for human prostate cancer therapeutics

Prostate

Volumn 34, Issue 4, 1998, Pages 259-269

  Rodriguez, Ronald ^a   Lim, Ho Yeong ^b   Bartkowski, Lisa M ^b   Simons, Jonathan W ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Apoptosis; Cell cycle; Diphtheria toxin; Gene therapy; P53; Prostate cancer

Indexed keywords

DIPHTHERIA TOXIN; PHOSPHOLIPASE A2; PROTEIN P53; PSEUDOMONAS EXOTOXIN; RICIN; SNAKE VENOM; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER SCREENING; CELL CYCLE; CELL PROLIFERATION; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; TOXIN ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL CYCLE; DIPHTHERIA TOXIN; DNA FRAGMENTATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031922185     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19980301)34:4<259::AID-PROS3>3.0.CO;2-C     Document Type: Article

References (33)

1. Parker SL, Tong T, Bolden S, Wingo P: Cancer statistics. Cancer JA Clin J 1997;47:5-27.
2. Yagoda A, Petrylak D: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-1109.
3. Scher HI, Fossa S: Prostate cancer in the era of prostate-specific antigen. Curr Opin Oncol 1995;7:281-291.
4. Coffey DS, Isaacs JT: Theory-prostate tumor biology and cell kinetics. Urology 1981;17:40-53.
5. Berges RR, Vukanovic J, Epstein JI, CarMichel M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT: Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-480.
6. Shackney SE, McCormack GW, Cuchural GJ: Growth rate patterns of solid tumors and their relation to responsiveness to therapy. Ann Intern Med 1978;89:107-121.
7. Isaacs JT, Schulze H, Coffey DS: Development of androgen resistance in prostatic cancer. In Murphy G, Khoury S, Kiess R, Chatelain C, Denis L (eds): "Prostate Cancer, Part A: Research, Endocrine Treatment, and Histopathology." New York: Alan R. Liss, 1987, pp 21-31.
8. Schuur ER, Henderson GA, Kmetec LA, Miller JD, Lamparski HG, Henderson DR: Prostate-specific antigen expression is regulated by an upstream enhancer. J Biol Chem 1996;271:7043-7051.
9. Pang S, Taneja S, Dardashti K, Cohan P, Kaboo R, Sokoloff M, Tso CL, Dekernion JB, Belldegrun AS: Prostate tissue specificity of the prostate-specific antigen promoter isolated from a patient with prostate cancer. Hum Gene Ther 1995;6:1417-1426.
10. Denmeade SR, Lin XS, Isaacs JT: Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-265.
11. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT: The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 1994;54:6167-6175.
12. Brinkmann U, Gallo M, Brinkmann E, Kunwar S, Pastan I: A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin. Proc Natl Acad Sci USA 1993;90:547-551.
13. Bander NH: Current status of monoclonal antibodies for imaging and therapy of prostate cancer. Semin Oncol 1994;21:607-612.
14. Gendimenico GJ, Bouquin PL, Tramposch KM: Diphenylamine-colorimetric method for DNA assay: A shortened procedure by incubating samples at 50 degrees C. Anal Biochem 1988;173:45-48.
15. Partin AW, Schoeniger JS, Mohler JL, Coffey DS: Fourier analysis of cell motility: Correlation of motility with metastatic potential. Proc Natl Acad Sci USA 1989;86:1254-1258.
16. Jackson DA: S-phase progression in synchronized human cells. Exp Cell Res 1995;22230:62-70.
17. Sphyris N, Lord JM, Wales R, Roberts LM: Mutational analysis of the Ricinus lectin B-chains. Galactose-binding ability of the 2 gamma subdomain of Ricinus communis agglutinin B-chain. J Biol Chem 1995;270:20292-20297.
18. Alexander RB, Nelson WG, Coffey DS: Tumor necrosis factor enhances the cytotoxicity of chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 1987;47:2403-2406.
19. Morimoto H, Bonavida B: Diphtheria toxin- and Pseudomonas a toxin-mediated apoptosis. ADP ribosylation of elongation factor-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factor-alpha. J Immunol 1992;149: 2089-2094.
20. Chang MP, Baldwin RL, Bruce C, Wisnieski BJ: Second cytotoxic pathway of diphtheria toxin suggested by nuclease activity. Science 1989;246:1165-1170.
21. Carroll AG, Voeller GJ, Sugars L, Gelmann EP: p53 oncogene mutations in three human prostate cancer cell lines. Prostate 1993;23:123-134.
22. Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB: An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res 1996;56:3814-3822.
23. McKeever B, Sarma R: Preliminary crystallographic investigation of the protein toxin from Corynebacterium diphtherias. J Biol Chem 1982;257:6923-6925.
24. Collier RJ, Westbrook EM, McKay DB, Eisenberg D: X-ray grade crystals of diphtheria toxin. J Biol Chem 1982;257:5283-5285.
25. Maxwell IH, Maxwell F, Glode LM: Regulated expression of a diphtheria Toxin A chain gene transfected into human cells: Possible strategy for inducing cancer sell suicide. Cancer Res 1986;46:4616-4664.
26. Duncan AM, Heddle JA: The frequency and distribution of apoptosis induced by three non-carcinogenic agents in mouse colonic crypts. Cancer Lett 1984;23:307-311.
27. Kochi SK, Collier RJ: DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis. Exp Cell Res 1993;208:296-302.
28. Chang MP, Bramhall J, Graves S, Bonavida B, Wisnieski BJ: Internucleosomal DNA cleavage precedes diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J Biol Chem 1989;264:15261-15267.
29. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LW, Hsieh JT, Tu SM, Campbell ML: Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52: 6940-6944.
30. Krajewska M, Krajewski S, Epstein JI, Shabaik A, Sauvageot J, Song K, Kitada S, Reed JC: Immunohistochemical analysis of bcl-2, bax, bcl-X and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-1576.
31. Kreitman RJ, Chaudhary VK, Waldmann TA, Hanchard B, Cranston B, FitzGerald DJ, Pastan I: Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia. Leukemia 1993;7:553-562.
32. Frankel AE, Tagge EP, Willingham MC: Clinical trials of targeted toxins. Semin Cancer Biol 1995;5:307-317.
33. Kreitman RJ, Pastan I: Recombinant toxins. Adv Pharmacol 1994;28:193-219.